VERA THERAPEUTICS INC

VERA21 Jan 2025
Healthcare
$34.13
+0.01 (+0.69%)
Lowest Today
$33.36
Highest Today
$34.13
Today’s Open
$34.13
Prev. Close
$33.37
52 Week High
$51.61
52 Week Low
$15.37
To Invest in VERA THERAPEUTICS INC

VERA THERAPEUTICS INC

Healthcare
VERA21 Jan 2025
+0.01 (+0.69%)
1M
3M
6M
1Y
5Y
Low
$33.36
Day’s Range
High
$34.12
33.36
52 Week Low
$15.37
52-Week Range
52 Week High
$51.61
15.37
1 Day
-
1 Week
-4.16%
1 month return
-20.68%
3 month return
-18.45%
6 month return
-3.52%
1 Year return
+123.29%
3 Years return
+65.8%
5 Years return
-
10 Years return
-
Institutional Holdings
venBio Select Advisor LLC
6.81
T. Rowe Price Associates, Inc.
6.22
BlackRock Inc
5.45
Sofinnova Ventures
4.41
FMR Inc
4.4
Vanguard Group Inc
4.07
COMMODORE CAPITAL LP
3.91

Market Status

Fundamentals
Market Cap
2113.09 mln
PB Ratio
7.31
PE Ratio
0
Enterprise Value
1814.69 mln
Total Assets
175.55 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Organisation
VERA THERAPEUTICS INC
Employees
82
Industry
Biotechnology
CEO
Dr. Marshall W. Fordyce M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities